NovelStem International (OTCMKTS:NSTM – Get Free Report) and Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Profitability
This table compares NovelStem International and Edgewise Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NovelStem International | N/A | -124.84% | 6,900.07% |
| Edgewise Therapeutics | N/A | -32.55% | -31.04% |
Earnings and Valuation
This table compares NovelStem International and Edgewise Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NovelStem International | $10,000.00 | 54.26 | $2.38 million | $0.06 | 0.18 |
| Edgewise Therapeutics | N/A | N/A | -$167.79 million | ($1.66) | -19.52 |
NovelStem International has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than NovelStem International, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
NovelStem International has a beta of 2.38, indicating that its stock price is 138% more volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for NovelStem International and Edgewise Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NovelStem International | 0 | 0 | 0 | 0 | 0.00 |
| Edgewise Therapeutics | 1 | 1 | 5 | 2 | 2.89 |
Edgewise Therapeutics has a consensus price target of $39.67, indicating a potential upside of 22.43%. Given Edgewise Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than NovelStem International.
Summary
NovelStem International beats Edgewise Therapeutics on 6 of the 11 factors compared between the two stocks.
About NovelStem International
NovelStem International Corp., a development stage biotechnology holding company, focuses on development and commercialization of stem cell-based diagnostic technology for cancer treatments and to reduce resistance to chemotherapy. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018. NovelStem International Corp. was incorporated in 1993 and is headquartered in Boca Raton, Florida.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Receive News & Ratings for NovelStem International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovelStem International and related companies with MarketBeat.com's FREE daily email newsletter.
